

Genesis Pharmaceuticals Enterprises, Inc.
Form 8-K
February 19, 2008

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549**

FORM 8-K

**CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934**

Date of report (Date of earliest event reported): February 15, 2008

GENESIS PHARMACEUTICALS ENTERPRISES, INC.

(Exact name of registrant as specified in Charter)

Florida (State or other jurisdiction of incorporation or organization)	<u>333-86347</u> (Commission File No.)	<u>65-1130026</u> (IRS Employee Identification No.)
---	--	--

**Middle Section, Longmao Street, Area A, Laiyang Waixiangxing Industrial Park
Laiyang City, Yantai, Shandong Province, People's Republic of China 710075
(Address of Principal Executive Offices)**

(0086)535-7282997
(Issuer Telephone number)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - Soliciting material pursuant to Rule 14a-12(b) under the Exchange Act (17 CFR 240.14a-12(b))
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

Item 8.01

OTHER EVENTS

On February 15, 2008, we issued a press release discussing our results of operation for the quarter ended December 31, 2007. The full text of the press release is set forth in Exhibit 99.1 hereto and incorporated herein by reference.

Item 9.01

FINANCIAL STATEMENTS AND EXHIBITS

(d)	Number	Exhibit	Description
	99.1		Press Release dated February 15, 2008

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: February 15, 2008

Genesis Pharmaceuticals Enterprises, Inc.

By: /s/ Elsa Sung

Elsa Sung
Chief Financial Officer
